Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.

Abstract

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.

• Authors: Joseph S Solomkin, Angie Sway, Kenneth Lawrence, Melanie Olesky, Sergey Izmailyan, Larry Tsai
• Journal: Future microbiology (Future Microbiol) Vol. 14 Pg. 1293-1308 (10 2019) ISSN: 1746-0921 [Electronic] England
• PMID: 31570004 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Tetracyclines
• eravacycline
• beta-Lactamases
• Meropenem
• Ertapenem

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (therapeutic use)
• Carbapenems (therapeutic use)
• Data Interpretation, Statistical
• Drug Resistance, Multiple, Bacterial
• Enterobacteriaceae (drug effects, enzymology)
• Ertapenem (therapeutic use)
• Female
• Humans
• Intraabdominal Infections (complications, drug therapy, microbiology)
• Male
• Meropenem (therapeutic use)
• Microbial Sensitivity Tests
• Middle Aged
• Prospective Studies
• Tetracyclines (therapeutic use)
• Young Adult
• beta-Lactamases